Suppr超能文献

嗜铬细胞瘤和副神经节瘤。

Pheochromocytoma and paraganglioma.

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, University of Arkansas for Medical Sciences, Arkansas Cancer Research Center, AR, USA.

出版信息

Prog Brain Res. 2010;182:343-73. doi: 10.1016/S0079-6123(10)82015-1.

Abstract

Pheochromocytoma is a very special kind of tumor full of duplicity. On the one hand it represents its own microworld with unique clinical, biochemical and pathological features, while on the other it constitutes a tremendously significant part of whole body system, playing a vital role for practically every organ system. It has a very special character - sometimes like a child it can be sweet and predictable, while at times it can behave like a deadly wild beast, crashing and tearing everything on its path in a fierce rage. It also consists of the amazingly intelligent neuroendocrine cells that possess a magical ability to make miraculous substances of many kinds. But most of all, it is a system that is able to drive our curiosity and the itch of "Cogito, ergo sum" to limitless depths and year by year it still amazes us with new and unexpected discoveries that move our understanding of multiple pathways and metabolic events closer to the ultimate truth. Recent discoveries of succinate dehydrogenase (SHD) and prolyl hydroxylase (PHD) mutations, for example, propelled our understanding of neuroendocrine tumorigenesis as a whole, as well as physiology of mitochondrial respiratory chain and phenomenon of pseudohypoxia in particular. Good old discoveries make their way from dusty repositories to shine with new meaning, appropriate for the current level of knowledge. This acquired wisdom makes us better physicians - knowing the specific expression makeup of catecholamine transporters, GLUTs and SRIFs allows for better tailored imaging and therapeutic manipulations. There are still long ways to go, keeping in mind that pheochromocytoma is but so very special, and we are optimistic and expect many great things to come.

摘要

嗜铬细胞瘤是一种非常特殊的肿瘤,充满了两面性。一方面,它代表了自身具有独特临床、生化和病理特征的微观世界,另一方面,它又是全身系统中极其重要的一部分,对几乎每一个器官系统都起着至关重要的作用。它具有非常特殊的性质——有时它像孩子一样可爱、可预测,而有时它又像凶猛的野兽一样,狂暴地摧毁它所经过的一切。它还由具有神奇能力的神经内分泌细胞组成,能够产生多种奇迹般的物质。但最重要的是,它是一个能够激发我们的好奇心和“我思故我在”的欲望的系统,将我们的认知推向无限的深度,而且它每年都会用新的、意想不到的发现让我们感到惊讶,这些发现使我们对多种途径和代谢事件的理解更接近最终的真理。例如,琥珀酸脱氢酶(SDH)和脯氨酰羟化酶(PHD)突变的最近发现,推动了我们对整个神经内分泌肿瘤发生的理解,以及对线粒体呼吸链生理学和假性缺氧现象的理解。例如,琥珀酸脱氢酶(SDH)和脯氨酰羟化酶(PHD)突变的最近发现,推动了我们对整个神经内分泌肿瘤发生的理解,以及对线粒体呼吸链生理学和假性缺氧现象的理解。例如,琥珀酸脱氢酶(SDH)和脯氨酰羟化酶(PHD)突变的最近发现,推动了我们对整个神经内分泌肿瘤发生的理解,以及对线粒体呼吸链生理学和假性缺氧现象的理解。例如,琥珀酸脱氢酶(SDH)和脯氨酰羟化酶(PHD)突变的最近发现,推动了我们对整个神经内分泌肿瘤发生的理解,以及对线粒体呼吸链生理学和假性缺氧现象的理解。例如,琥珀酸脱氢酶(SDH)和脯氨酰羟化酶(PHD)突变的最近发现,推动了我们对整个神经内分泌肿瘤发生的理解,以及对线粒体呼吸链生理学和假性缺氧现象的理解。例如,琥珀酸脱氢酶(SDH)和脯氨酰羟化酶(PHD)突变的最近发现,推动了我们对整个神经内分泌肿瘤发生的理解,以及对线粒体呼吸链生理学和假性缺氧现象的理解。例如,琥珀酸脱氢酶(SDH)和脯氨酰羟化酶(PHD)突变的最近发现,推动了我们对整个神经内分泌肿瘤发生的理解,以及对线粒体呼吸链生理学和假性缺氧现象的理解。

例如,琥珀酸脱氢酶(SDH)和脯氨酰羟化酶(PHD)突变的最近发现,推动了我们对整个神经内分泌肿瘤发生的理解,以及对线粒体呼吸链生理学和假性缺氧现象的理解。

旧的发现也从尘封的档案中重新焕发生机,赋予了它们新的意义,以适应当前的知识水平。这种获得的智慧使我们成为更好的医生——了解儿茶酚胺转运体、GLUTs 和 SRIFs 的特定表达组成,允许进行更好的定制成像和治疗操作。还有很长的路要走,要记住,嗜铬细胞瘤是非常特殊的,我们持乐观态度,并期待着许多伟大的事情的到来。

相似文献

1
Pheochromocytoma and paraganglioma.
Prog Brain Res. 2010;182:343-73. doi: 10.1016/S0079-6123(10)82015-1.
2
Pheochromocytoma and paraganglioma: recent progress and new vistas for improved patient care.
Horm Metab Res. 2012 May;44(5):325-7. doi: 10.1055/s-0031-1299759. Epub 2012 May 7.
3
Succinate-Dehydrogenase Deficient Paragangliomas/Pheochromocytomas: Genetics, Clinical Aspects and Mini- Review.
Pediatr Endocrinol Rev. 2017 Mar;14(3):312-325. doi: 10.17458/per.vol14.2017.RK.succinatedehydrogenase.
4
Gene targeting through o-methylated catecholamine metabolite patterns.
Clin Chem. 2011 Mar;57(3):361-2. doi: 10.1373/clinchem.2010.159178. Epub 2011 Jan 18.
5
Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma.
Cell Tissue Res. 2018 May;372(2):393-401. doi: 10.1007/s00441-018-2791-4. Epub 2018 Feb 15.
6
Clinical Presentation and Treatment Outcomes of Children and Adolescents With Pheochromocytoma and Paraganglioma in a Single Center in Korea.
Front Endocrinol (Lausanne). 2021 Jan 29;11:610746. doi: 10.3389/fendo.2020.610746. eCollection 2020.
7
MANAGEMENT OF CATECHOLAMINE-SECRETING TUMORS IN PREGNANCY: A REVIEW.
Endocr Pract. 2016 Mar;22(3):357-70. doi: 10.4158/EP151009.RA. Epub 2015 Nov 4.
8
Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
Clin Genet. 2020 Jan;97(1):39-53. doi: 10.1111/cge.13553. Epub 2019 May 6.
9
Metastatic pheochromocytoma and paraganglioma: Integrating tumor biology in clinical practice.
Mol Cell Endocrinol. 2024 Oct 1;592:112344. doi: 10.1016/j.mce.2024.112344. Epub 2024 Aug 31.
10
Disease monitoring of patients with pheochromocytoma or paraganglioma by biomarkers and imaging studies.
Best Pract Res Clin Endocrinol Metab. 2020 Mar;34(2):101347. doi: 10.1016/j.beem.2019.101347. Epub 2019 Oct 21.

引用本文的文献

1
An uncommon case of pheochromocytoma with positive biochemical workup and absence of tumor.
Endocrinol Diabetes Metab Case Rep. 2025 Sep 2;2025(3). doi: 10.1530/EDM-25-0027. Print 2025 Jul 1.
2
Management of Pheochromocytoma in The Setting of Acute Stroke.
AACE Clin Case Rep. 2020 Dec 28;4(3):245-248. doi: 10.4158/ACCR-2017-0077. eCollection 2018 May-Jun.
3
Management of concurrent aortic stenosis and pheochromocytoma.
BMJ Case Rep. 2022 Sep 6;15(9):e250472. doi: 10.1136/bcr-2022-250472.
5
Neuropeptide Y in cancer-biological functions and potential clinical implications.
Cancer Metastasis Rev. 2025 Jan 6;44(1):21. doi: 10.1007/s10555-024-10237-z.
6
An Incidental Finding of a Large Pheochromocytoma in an Asymptomatic Male: A Case Report.
Cureus. 2024 Dec 13;16(12):e75659. doi: 10.7759/cureus.75659. eCollection 2024 Dec.
7
Perioperative Blood Pressure Management Recommendations in Pediatric Pheochromocytoma: A 10-Year Narrative Review.
Kidney Blood Press Res. 2025;50(1):61-82. doi: 10.1159/000542897. Epub 2024 Dec 3.
8
Screening and treatment of endocrine hypertension focusing on adrenal gland disorders: a narrative review.
J Yeungnam Med Sci. 2024 Oct;41(4):269-278. doi: 10.12701/jyms.2024.00752. Epub 2024 Sep 19.
9
Navigating new horizons: Prospects of NET-targeted radiopharmaceuticals in precision medicine.
Theranostics. 2024 May 19;14(8):3178-3192. doi: 10.7150/thno.96743. eCollection 2024.
10
Editorial: Case reports in hypertension: 2022.
Front Cardiovasc Med. 2023 May 22;10:1210740. doi: 10.3389/fcvm.2023.1210740. eCollection 2023.

本文引用的文献

1
A substance with sympathin E properties in spleen extracts.
Nature. 1946 Mar 23;157:369. doi: 10.1038/157369b0.
3
[About the sympathicomimetric pressure principle of urine (urosympathin)].
Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1947;204(1-3):228-43.
4
Takotsubo cardiomyopathy--the current state of knowledge.
Int J Cardiol. 2010 Jul 9;142(2):120-5. doi: 10.1016/j.ijcard.2009.11.040. Epub 2010 Jan 3.
5
Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma.
J Clin Endocrinol Metab. 2010 Jan;95(1):238-45. doi: 10.1210/jc.2009-1850. Epub 2009 Nov 6.
6
Pheochromocytoma-induced cardiomyopathy is modulated by the synergistic effects of cell-secreted factors.
Circ Heart Fail. 2009 Mar;2(2):121-8. doi: 10.1161/CIRCHEARTFAILURE.108.813261. Epub 2009 Feb 10.
7
The Warburg effect is genetically determined in inherited pheochromocytomas.
PLoS One. 2009 Sep 18;4(9):e7094. doi: 10.1371/journal.pone.0007094.
8
SDH5 mutations and familial paraganglioma: somewhere Warburg is smiling.
Cancer Cell. 2009 Sep 8;16(3):180-2. doi: 10.1016/j.ccr.2009.08.013.
9
SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma.
Science. 2009 Aug 28;325(5944):1139-42. doi: 10.1126/science.1175689. Epub 2009 Jul 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验